FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783023789> ?p ?o ?g. }

• W2783023789 endingPage "3743" @default.
• W2783023789 startingPage "3743" @default.
• W2783023789 abstract "Abstract Background: Patients with sickle cell disease (SCD) and beta (β)-thalassemia often require regular blood transfusions; however, each unit of blood contains approximately 200 mg of iron, which can rapidly lead to iron overload (IO). This can result in iron deposition in the heart, liver, and endocrine organs, ultimately leading to organ failure, including cardiac disease, liver fibrosis, and metabolic disorders. The introduction of iron chelation therapy (ICT) with deferoxamine (DFO) and more recently deferiprone (DFP) and deferasirox (DFX) has had a significant impact on IO, demonstrating reductions in serum ferritin level and liver iron content. Although ICT has become the standard of care over the past few decades, there are limited data on the effects of these agents on overall survival. The objective of this systematic review is to evaluate the impact of ICT on survival in patients with transfusion-dependent SCD or β-thalassemia. Methods: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols(PRISMA-P) guidelines. Electronic databases, including Embase, PubMed, Cochrane Library, and the World Health Organization (WHO) Clinical Trials Search Portal, along with American Society of Hematology annual meeting abstracts from 2010-2015 were searched to identify English language articles that were relevant to the topic. Search terms included “sickle cell anemia” or “SCA,” “sickle cell disease” or “SCD,” “beta thalassemia” or “thalassemia,” “iron chelation,” “iron overload,” “survival,” “death,” “study,” and “trial.” Abstracts identified by the literature were independently reviewed and only articles with unanimous support were included; when the eligibility of an abstract was disputed, a full copy of the article was retrieved for review. References were excluded for lack of evidence of survival analysis, comparison between regimens, or if trials had fewer than 25 patients. Details of the included studies were collected for categorization. Although a meta-analysis of the data was initially planned, there were too few studies with similar study parameters to complete the analysis. Results: For SCD, the literature search yielded 203 articles of which 6 were deemed relevant (Figure 1). Of these, 3 were excluded and 3 (published between 2001 and 2014) were included. Reasons for exclusion included small patient number, no comparator, and being a theoretical paper. Only 1 of the 3 was a randomized clinical trial (RCT). For β-thalassemia, theliterature analyses yielded 398 articles of which 40 were deemed relevant (Figure 2). After reviewing the articles, 22 were excluded while 18 (published between 1991 and 2015) were included. Reasons for exclusion included small patient number, no comparator, no survival data, no chelation data, or a focus on hematopoietic stem cell or bone marrow transplantation. Only 3 of the 18 were RCTs; the remainder were retrospective and/or longitudinal studies. Most data on effectiveness of ICT were from longitudinal studies that suggest treatment outcomes have improved significantly over time mainly due to the introduction of new and improved iron chelation agents, including oral treatments and combination therapy. Effectiveness was also investigated in studies evaluating treatment compliance that suggest survival is improved in patients compliant to ICT. Compliance has been enhanced with the introduction of oral agents such as DFP and DFX compared with DFO, which requires daily subcutaneous injections. Conclusions: This systematic review identified few RCTs of ICT reporting survival in SCD and β-thalassemia. Despite limited data, the available literature suggests that ICT improves overall survival in SCD and β-thalassemia. Survival may also have been affected by factors such as hydroxyurea usage and the number of blood transfusions. Newer oral treatments have improved compliance, shown to be an important factor in survival, although there have not been any prospective long-term RCTs adequately powered to compare the efficacy among available iron chelation agents in either SCD or β-thalassemia. Download : Download high-res image (122KB) Download : Download full-size image Disclosures Ballas: Novartis: Honoraria, Speakers Bureau. Zeidan: Takeda: Speakers Bureau; AbbVie, Otsuka, Pfizer, Gilead, Celgene, Ariad, Incyte: Consultancy, Honoraria; Otsuka: Consultancy." @default.
• W2783023789 created "2018-01-26" @default.
• W2783023789 creator A5000296770 @default.
• W2783023789 creator A5013923213 @default.
• W2783023789 creator A5067521829 @default.
• W2783023789 creator A5090681994 @default.
• W2783023789 date "2017-12-07" @default.
• W2783023789 modified "2023-09-26" @default.
• W2783023789 title "A Systematic Review of the Effect of Iron Chelation Therapy on Survival in Patients with Sickle Cell Disease and β-Thalassemia" @default.
• W2783023789 doi "https://doi.org/10.1182/blood.v130.suppl_1.3743.3743" @default.
• W2783023789 hasPublicationYear "2017" @default.
• W2783023789 type Work @default.
• W2783023789 sameAs 2783023789 @default.
• W2783023789 citedByCount "0" @default.
• W2783023789 crossrefType "journal-article" @default.
• W2783023789 hasAuthorship W2783023789A5000296770 @default.
• W2783023789 hasAuthorship W2783023789A5013923213 @default.
• W2783023789 hasAuthorship W2783023789A5067521829 @default.
• W2783023789 hasAuthorship W2783023789A5090681994 @default.
• W2783023789 hasConcept C126322002 @default.
• W2783023789 hasConcept C168563851 @default.
• W2783023789 hasConcept C17744445 @default.
• W2783023789 hasConcept C177713679 @default.
• W2783023789 hasConcept C187212893 @default.
• W2783023789 hasConcept C189708586 @default.
• W2783023789 hasConcept C199539241 @default.
• W2783023789 hasConcept C2776478404 @default.
• W2783023789 hasConcept C2776517179 @default.
• W2783023789 hasConcept C2776672577 @default.
• W2783023789 hasConcept C2777218474 @default.
• W2783023789 hasConcept C2777799968 @default.
• W2783023789 hasConcept C2777940137 @default.
• W2783023789 hasConcept C2778248108 @default.
• W2783023789 hasConcept C2779134260 @default.
• W2783023789 hasConcept C2779473830 @default.
• W2783023789 hasConcept C2780014101 @default.
• W2783023789 hasConcept C2781053155 @default.
• W2783023789 hasConcept C535046627 @default.
• W2783023789 hasConcept C71924100 @default.
• W2783023789 hasConceptScore W2783023789C126322002 @default.
• W2783023789 hasConceptScore W2783023789C168563851 @default.
• W2783023789 hasConceptScore W2783023789C17744445 @default.
• W2783023789 hasConceptScore W2783023789C177713679 @default.
• W2783023789 hasConceptScore W2783023789C187212893 @default.
• W2783023789 hasConceptScore W2783023789C189708586 @default.
• W2783023789 hasConceptScore W2783023789C199539241 @default.
• W2783023789 hasConceptScore W2783023789C2776478404 @default.
• W2783023789 hasConceptScore W2783023789C2776517179 @default.
• W2783023789 hasConceptScore W2783023789C2776672577 @default.
• W2783023789 hasConceptScore W2783023789C2777218474 @default.
• W2783023789 hasConceptScore W2783023789C2777799968 @default.
• W2783023789 hasConceptScore W2783023789C2777940137 @default.
• W2783023789 hasConceptScore W2783023789C2778248108 @default.
• W2783023789 hasConceptScore W2783023789C2779134260 @default.
• W2783023789 hasConceptScore W2783023789C2779473830 @default.
• W2783023789 hasConceptScore W2783023789C2780014101 @default.
• W2783023789 hasConceptScore W2783023789C2781053155 @default.
• W2783023789 hasConceptScore W2783023789C535046627 @default.
• W2783023789 hasConceptScore W2783023789C71924100 @default.
• W2783023789 hasLocation W27830237891 @default.
• W2783023789 hasOpenAccess W2783023789 @default.
• W2783023789 hasPrimaryLocation W27830237891 @default.
• W2783023789 hasRelatedWork W1576226830 @default.
• W2783023789 hasRelatedWork W1595028412 @default.
• W2783023789 hasRelatedWork W2024808990 @default.
• W2783023789 hasRelatedWork W2053431904 @default.
• W2783023789 hasRelatedWork W2059688455 @default.
• W2783023789 hasRelatedWork W2100786476 @default.
• W2783023789 hasRelatedWork W2111485128 @default.
• W2783023789 hasRelatedWork W2116024007 @default.
• W2783023789 hasRelatedWork W2150434366 @default.
• W2783023789 hasRelatedWork W2167467743 @default.
• W2783023789 hasRelatedWork W2557836944 @default.
• W2783023789 hasRelatedWork W2605578529 @default.
• W2783023789 hasRelatedWork W2885722031 @default.
• W2783023789 hasRelatedWork W2922112864 @default.
• W2783023789 hasRelatedWork W2925267104 @default.
• W2783023789 hasRelatedWork W2987424626 @default.
• W2783023789 hasRelatedWork W2988761910 @default.
• W2783023789 hasRelatedWork W3003119562 @default.
• W2783023789 hasRelatedWork W3096384215 @default.
• W2783023789 hasRelatedWork W339295716 @default.
• W2783023789 hasVolume "130" @default.
• W2783023789 isParatext "false" @default.
• W2783023789 isRetracted "false" @default.
• W2783023789 magId "2783023789" @default.
• W2783023789 workType "article" @default.